berezko / iStockphoto.com
NPS Pharmaceuticals suffered a knock-back yesterday, when the US Court of Appeals for the Federal Circuit affirmed a decision which found that claims covering a patent owned by NPS were unpatentable.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at firstname.lastname@example.org
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Kyle Bass, Coalition for Affordable Drugs, PTAB, Gattex, NPS Pharmaceuticals, Shire, inter partes review, US Court of Appeals for the Federal Ciruit